Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press16410.17650/2313-805X-2018-5-3-40-50RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИRelation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancerВзаимосвязь компонентов EGFR/PI3K/Akt-сигнального пути с эффективностью терапии тамоксифеном у больных эстрогензависимым раком молочной железыhttps://orcid.org/0000-0003-3009-2404DronovaT. A.ДроноваТ. А.
Russian Federation
tanyadronova@mail.ruhttps://orcid.org/0000-0002-0562-3878BabyshkinaN. N.БабышкинаН. Н.
Russian Federation
https://orcid.org/0000-0001-9429-9813ZavyalovaM. V.ЗавьяловаМ. В.
Russian Federation
https://orcid.org/0000-0002-9468-1980PatalyakS. V.ПаталякС. В.
Russian Federation
https://orcid.org/0000-0003-4382-5697SlonimskayaE. M.СлонимскаяЕ. М.
Russian Federation
https://orcid.org/0000-0003-1526-9013CherdyntsevaN. V.ЧердынцеваН. В.
Russian Federation
https://orcid.org/0000-0003-0898-3075KzhyshkowskaJ. G.КжышковскаЮ. Г.
Russian Federation
Саncеr Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesНаучно-исследовательский институт онкологииФГБНУ «Томский национальный исследовательский медицинский центр РАНNational Research Tomsk State UniversityФГАОУ ВО «Национальный исследовательский Томский государственный университет»Siberian State Medical UniversityФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииUniversity of Heidelberg, Mannheim, GermanyУниверситет ГейдельбергаГермания, Маннхайм150920185340501011201810112018Copyright ©; 2018, Dronova T.A., Babyshkina N.N., Zavyalova M.V., Patalyak S.V., Slonimskaya E.M., Cherdyntseva N.V., Kzhyshkowska J.G.Copyright ©; 2018, Дронова Т.А., Бабышкина Н.Н., Завьялова М.В., Паталяк С.В., Слонимская Е.М., Чердынцева Н.В., Кжышковска Ю.Г.2018Dronova T.A., Babyshkina N.N., Zavyalova M.V., Patalyak S.V., Slonimskaya E.M., Cherdyntseva N.V., Kzhyshkowska J.G.Дронова Т.А., Бабышкина Н.Н., Завьялова М.В., Паталяк С.В., Слонимская Е.М., Чердынцева Н.В., Кжышковска Ю.Г.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/164

estrogen-dependent breast cancertamoxifenEGFR/PI3K/AKT signalinggene polymorphismэстрогензависимый рак молочной железытамоксифенEGFR/PI3K/Akt-сигнальный каскадполиморфизм геновРабота выполнена при финансовой поддержке Гранта РФФИ № 17-29-06037 офи_м «Геномные механизмы регуляции опухолевой прогрессии рака молочной железы в условиях лекарственной терапии».1. Senkus E., Kyriakides S., PenaultLlorca F. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi7–vi23. DOI: 10.1093/annonc/mdt284. PMID: 26314782.Senkus E., Kyriakides S., PenaultLlorca F. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi7–vi23. DOI: 10.1093/annonc/mdt284. PMID: 26314782.2. Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant Endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on ovarian suppression. J Clin Oncol 2016;34(14):1689–701. DOI: 10.1200/JCO.2015.65.9573. PMID: 26884586.Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant Endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on ovarian suppression. J Clin Oncol 2016;34(14):1689–701. DOI: 10.1200/JCO.2015.65.9573. PMID: 26884586.3. Crew K.D., Albain K.S., Hershman D.L. et al. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer 2017;3(20):1–7. DOI: 10.1038/s41523-017-0021-y. PMID: 28649660.Crew K.D., Albain K.S., Hershman D.L. et al. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer 2017;3(20):1–7. DOI: 10.1038/s41523-017-0021-y. PMID: 28649660.4. Pan H., Gray R., Braybrooke J. et al. 20- year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836–46. DOI: 10.1056/NEJMoa1701830. PMID: 29117498.Pan H., Gray R., Braybrooke J. et al. 20- year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836–46. DOI: 10.1056/NEJMoa1701830. PMID: 29117498.5. Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 2012;20(3): 256–7. DOI: 10.4062/biomolther. 2012.20.3.256. PMID: 24130921.Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 2012;20(3): 256–7. DOI: 10.4062/biomolther. 2012.20.3.256. PMID: 24130921.6. Velloso F.J., Bianco A.F., Farias J.O. et al. The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. Oncol Targets Ther 2017;10:5491–524. DOI: 10.2147/OTT.S142154. PMID: 29200866.Velloso F.J., Bianco A.F., Farias J.O. et al. The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. Oncol Targets Ther 2017;10:5491–524. DOI: 10.2147/OTT.S142154. PMID: 29200866.7. Wee P., Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers(Basel) 2017;9(5):52. DOI: 10.3390/cancers9050052. PMID: 28513565.Wee P., Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers(Basel) 2017;9(5):52. DOI: 10.3390/cancers9050052. PMID: 28513565.8. Paplomata E., O’Regan R. The PI3K/ AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014;6(4):154–66. DOI: 10.1177/1758834014530023. PMID: 25057302.Paplomata E., O’Regan R. The PI3K/ AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014;6(4):154–66. DOI: 10.1177/1758834014530023. PMID: 25057302.9. Lee J.J., Loh K., Yap Y.S. PI3K/Akt/ mTOR inhibitors in breast cancer. Cancer Biol Med 2015;12(4):342–54. DOI: 10.7497/j.issn.2095-3941. 2015.0089. PMID: 26779371.Lee J.J., Loh K., Yap Y.S. PI3K/Akt/ mTOR inhibitors in breast cancer. Cancer Biol Med 2015;12(4):342–54. DOI: 10.7497/j.issn.2095-3941. 2015.0089. PMID: 26779371.10. Giltnane J.M., Ryden L., Cregger M. et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007;25:3007–14. DOI: 10.1200/ JCO.2006.08.9938. PMID: 17634479.Giltnane J.M., Ryden L., Cregger M. et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007;25:3007–14. DOI: 10.1200/ JCO.2006.08.9938. PMID: 17634479.11. Massarweh S., Osborne C.K., Creighton C.J. et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68(3):826–33. DOI: 10.1158/0008-5472.CAN-07-2707. PMID: 18245484.Massarweh S., Osborne C.K., Creighton C.J. et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68(3):826–33. DOI: 10.1158/0008-5472.CAN-07-2707. PMID: 18245484.12. Kim S., Lee J., Oh S.J. et al. Differential effect of EGFR inhibitors on tamoxifenresistant breast cancer cells. Oncol Rep 2015;34(3):1613–9. DOI: 10.3892/or.2015.4116. PMID: 26166014.Kim S., Lee J., Oh S.J. et al. Differential effect of EGFR inhibitors on tamoxifenresistant breast cancer cells. Oncol Rep 2015;34(3):1613–9. DOI: 10.3892/or.2015.4116. PMID: 26166014.13. Babyshkina N., Vtorushin S., Zavyalova M. et al. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clin Exp Med 2017;17(3):383–93. DOI: 10.1007/s10238-016-0428-z. PMID: 27225751.Babyshkina N., Vtorushin S., Zavyalova M. et al. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clin Exp Med 2017;17(3):383–93. DOI: 10.1007/s10238-016-0428-z. PMID: 27225751.14. Kirkegaard T., Witton C.J., McGlynn L.M. et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139–46. DOI: org/10.1002/path.1829. PMID: 16088978.Kirkegaard T., Witton C.J., McGlynn L.M. et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139–46. DOI: org/10.1002/path.1829. PMID: 16088978.15. Tanic N., Milovanovic Z., Tanic N. et al. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol Ther 2012;13(12):1165–74. DOI: 10.4161/cbt.21346. PMID: 22892847.Tanic N., Milovanovic Z., Tanic N. et al. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol Ther 2012;13(12):1165–74. DOI: 10.4161/cbt.21346. PMID: 22892847.16. Li T., Zhao J., Yang J. et al. A Metaanalysis of the association between ESR1 genetic variants and the risk of breast cancer. PLoS One 2016;11(4):e0153314. DOI: 10.1371/journal.pone.0153314. PMID: 27070141.Li T., Zhao J., Yang J. et al. A Metaanalysis of the association between ESR1 genetic variants and the risk of breast cancer. PLoS One 2016;11(4):e0153314. DOI: 10.1371/journal.pone.0153314. PMID: 27070141.17. Hsiao W.C., Young K.C., Lin S.L. et al. Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res 2004;6(3):180–6. DOI: 10.1186/bcr770. PMID: 15084241.Hsiao W.C., Young K.C., Lin S.L. et al. Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res 2004;6(3):180–6. DOI: 10.1186/bcr770. PMID: 15084241.18. Fernandez L.P., Milne R.L., Barroso E. et al. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 2006;119(2):467–71. DOI: 10.1002/ijc. 21847. PMID: 16477637.Fernandez L.P., Milne R.L., Barroso E. et al. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 2006;119(2):467–71. DOI: 10.1002/ijc. 21847. PMID: 16477637.19. Anghel A., Raica M., Narita D. Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer. Neoplasma 2010;57(4):306–15. PMID: 20429621.Anghel A., Raica M., Narita D. Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer. Neoplasma 2010;57(4):306–15. PMID: 20429621.20. Chong K., Subramanian A., Sharma A. et al. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifenresistance in ER-positive breast cancer. Anticancer Res 2011;31(1):23–32. PMID: 21273576.Chong K., Subramanian A., Sharma A. et al. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifenresistance in ER-positive breast cancer. Anticancer Res 2011;31(1):23–32. PMID: 21273576.21. Xuan Q.J., Wang J.X., Nanding A. et al. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. Pathol Oncol Res 2014;20(3):619–24. DOI: 10.1007/ s12253-013-9740-z. PMID: 24414992.Xuan Q.J., Wang J.X., Nanding A. et al. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. Pathol Oncol Res 2014;20(3):619–24. DOI: 10.1007/ s12253-013-9740-z. PMID: 24414992.22. Bae S.Y., Nam S.J., Lee S.K. et al. Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium: Report abstract Cancer Res 2017;77(4):9–36. DOI: 10.1158/1538-7445.Bae S.Y., Nam S.J., Lee S.K. et al. Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium: Report abstract Cancer Res 2017;77(4):9–36. DOI: 10.1158/1538-7445.23. van Agthoven T., Veldscholte J., Smid M. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009;114(1):23–30. DOI: 10.1007/s10549-008-9969-5. PMID: 18351453.van Agthoven T., Veldscholte J., Smid M. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009;114(1):23–30. DOI: 10.1007/s10549-008-9969-5. PMID: 18351453.24. van Agthoven T., Godinho M.F., Wulfkuhle J.D. et al. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int J Cancer 2012;131(9):1998–2007. DOI: 10.1002/ijc. 27489.van Agthoven T., Godinho M.F., Wulfkuhle J.D. et al. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int J Cancer 2012;131(9):1998–2007. DOI: 10.1002/ijc. 27489.25. Riggio M., Perrone M.C., Polo M.L. et al. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep 2017;7:44244. DOI: 10.1038/srep44244. PMID: 28287129.Riggio M., Perrone M.C., Polo M.L. et al. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep 2017;7:44244. DOI: 10.1038/srep44244. PMID: 28287129.26. Bostner J., Karlsson E., Pandiyan M.J. et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013;137(2):397– 406. DOI: 10.1007/s10549-012-2376-y. PMID: 23242584.Bostner J., Karlsson E., Pandiyan M.J. et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013;137(2):397– 406. DOI: 10.1007/s10549-012-2376-y. PMID: 23242584.